List of Excipients in Branded Drug BACTERIOSTATIC SODIUM CHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	BACTERIOSTATIC SODIUM CHLORIDE	sodium chloride	0409-1966	BENZYL ALCOHOL
Hospira Inc	BACTERIOSTATIC SODIUM CHLORIDE	sodium chloride	0409-1966	HYDROCHLORIC ACID
Hospira Inc	BACTERIOSTATIC SODIUM CHLORIDE	sodium chloride	0409-1966	WATER
HF Acquisition Co LLC DBA HealthFirst	BACTERIOSTATIC SODIUM CHLORIDE	bacteriostatic sodium chloride	51662-1257	BENZYL ALCOHOL
HF Acquisition Co LLC DBA HealthFirst	BACTERIOSTATIC SODIUM CHLORIDE	bacteriostatic sodium chloride	51662-1257	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	BACTERIOSTATIC SODIUM CHLORIDE	bacteriostatic sodium chloride	51662-1257	WATER

Generic Drugs Containing BACTERIOSTATIC SODIUM CHLORIDE

Company	Ingredient	NDC	Excipient
Fresenius Kabi USA LLC	sodium chloride	63323-924	BENZYL ALCOHOL
Fresenius Kabi USA LLC	sodium chloride	63323-924	HYDROCHLORIC ACID
Fresenius Kabi USA LLC	sodium chloride	63323-924	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in BACTERIOSTATIC SODIUM CHLORIDE?

# Of NDCs	Excipient
1	BENZYL ALCOHOL
1	HYDROCHLORIC ACID
1	SODIUM HYDROXIDE

Bacteriostatic Sodium Chloride Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Bacteriostatic Sodium Chloride Injection is a low-complexity, mature injectable product containing sodium chloride in water for injection and a preservative, typically benzyl alcohol. Its commercial value is driven by sterile manufacturing, preservative performance, container-closure quality, supply reliability, and compatibility data rather than novel pharmaceutical composition. The strongest opportunities are preservative-free alternatives, low-volume multi-dose presentations, specialty diluent platforms, contract manufacturing, and differentiated packaging.

What is Bacteriostatic Sodium Chloride Injection?

Bacteriostatic Sodium Chloride Injection USP is a sterile sodium chloride solution intended primarily as a diluent or vehicle for parenteral drugs. The product typically contains 0.9% sodium chloride and approximately 0.9% benzyl alcohol as an antimicrobial preservative.

Attribute	Typical specification
Active component	Sodium chloride, 0.9% w/v
Preservative	Benzyl alcohol, commonly 0.9%
Dosage form	Sterile injectable solution
Primary role	Diluent or vehicle for injectable drugs
Common container	Multi-dose glass vial or polymer vial
Approximate osmolarity	About 308 mOsm/L
Typical pH range	Approximately 4.5 to 7.0
Principal regulatory concern	Benzyl alcohol exposure and preservative suitability
Main commercial barrier	Sterile injectable manufacturing and quality compliance

The product is different from preservative-free 0.9% sodium chloride injection used for direct fluid replacement. Bacteriostatic sodium chloride is generally selected when repeated withdrawals from a vial are needed and the formulation permits a preservative.

Product labeling restricts use in neonates because benzyl alcohol exposure has been associated with serious toxicity in premature infants and low-birth-weight infants. Labeling also limits use in certain sensitive administration routes, including intrathecal use, unless specifically supported by the product and clinical context (Pfizer, 2023).

Which excipients are used in Bacteriostatic Sodium Chloride?

The core formulation has a narrow excipient profile. Sodium chloride provides tonicity, water for injection is the vehicle, and benzyl alcohol supplies antimicrobial preservation.

Sodium chloride

Sodium chloride is both the principal formulation ingredient and the tonicity-adjusting agent. A 0.9% solution approximates isotonicity with blood and is widely accepted for parenteral dilution.

The formulation strategy is technically simple, but small deviations can affect osmolality, pH, precipitation behavior, and compatibility with the drug being diluted. Manufacturing controls should address:

• Sodium chloride assay and identity
• Osmolality
• Particulate matter
• Bacterial endotoxins
• Sterility
• Fill volume
• Container-closure integrity
• Visual appearance
• pH and preservative concentration

Benzyl alcohol

Benzyl alcohol is the principal commercial differentiator between bacteriostatic and preservative-free sodium chloride presentations. Its functions are to reduce microbial growth after vial puncture and support multi-dose use within the labeled storage and handling conditions.

The preservative creates several liabilities:

• Neonatal toxicity concerns
• Restrictions for intrathecal and certain specialized uses
• Potential incompatibility with sensitive active ingredients
• Benzyl alcohol concentration drift during storage
• Extractables and leachables considerations
• Need for preservative-effectiveness testing
• Limits on use in populations requiring repeated or high-volume administration

The formulation must demonstrate that benzyl alcohol remains chemically stable and microbiologically effective through the proposed shelf life. USP <51> provides a standard framework for antimicrobial effectiveness testing, while USP <71> addresses sterility testing (United States Pharmacopeia, 2023).

Water for Injection

Water for Injection is a critical manufacturing material rather than a conventional excipient differentiated through branding. The water system must meet chemical, microbial, and endotoxin requirements. The highest operational risks are contamination control, system qualification, sanitization, and ongoing monitoring.

pH adjustment agents

Some products may use hydrochloric acid or sodium hydroxide for pH adjustment. These materials are generally present in low concentrations and do not create meaningful product differentiation unless they improve stability or compatibility for a specific drug class.

What excipient strategies can improve the product?

The most commercially useful strategy is not to add more excipients. It is to control the preservative and compatibility profile while preserving the clinical familiarity of 0.9% sodium chloride.

Strategy 1: Optimize benzyl alcohol concentration

A manufacturer can evaluate the lowest benzyl alcohol concentration that maintains antimicrobial effectiveness and product stability. A lower concentration may reduce exposure concerns, but it must pass preservative-effectiveness testing and support the proposed in-use period.

The business benefit is strongest when the product is positioned for adult and outpatient use where multi-dose access is valuable but preservative burden remains a purchasing concern.

Strategy 2: Develop a preservative-free line

A preservative-free presentation can target:

• Neonatal care
• Pediatric care
• Intrathecal or neuraxial workflows where permitted by labeling
• Ophthalmic or highly sensitive applications
• Hospital protocols that avoid benzyl alcohol
• Drug products with known preservative incompatibility

Preservative-free products generally require single-dose packaging or a validated sterile withdrawal system. Their manufacturing cost is higher, but the addressable market is broader in high-risk clinical settings.

Strategy 3: Use alternative antimicrobial systems cautiously

Alternative preservatives such as parabens, phenol, chlorobutanol, or metacresol may create new toxicity, compatibility, or regulatory problems. They are not direct substitutes on a one-for-one basis.

A new preservative system would require:

1. Antimicrobial effectiveness data
2. Compatibility data with the target drug classes
3. Toxicological justification
4. Container-closure assessment
5. Extractables and leachables testing
6. In-use stability data
7. Regulatory approval for the specific finished product

For a simple sodium chloride diluent, the cost and regulatory risk of replacing benzyl alcohol may exceed the value unless the new product targets a defined clinical segment.

Strategy 4: Improve container-closure performance

Container selection can provide more defensible commercial differentiation than the solution composition.

Relevant options include:

• Type I borosilicate glass vials
• Polymer vials
• Blow-fill-seal containers
• Low-sorption elastomer stoppers
• Integrated transfer devices
• Single-dose ampoules
• Small-volume ready-to-use vials
• Prefilled syringes where the use case supports them

The container must protect against evaporation, preservative loss, microbial ingress, particulate generation, and interaction with the stopper or vial surface. Container-closure integrity testing should be aligned with USP <1207> principles (United States Pharmacopeia, 2023).

What formulations are protected by patents?

Conventional bacteriostatic sodium chloride formulations have limited patent potential because sodium chloride, water for injection, benzyl alcohol, and their general use as an injectable diluent are longstanding technologies.

Potential IP area	Patent strength	Commercial relevance
Sodium chloride and water composition	Very low	Mature, broadly known formulation
Benzyl alcohol preservation	Very low for basic use	Known preservative application
Narrow preservative concentration range	Low to moderate	Requires demonstrated technical effect
Drug-specific compatibility formulation	Moderate	May protect a defined diluent-drug combination
Novel container or closure	Moderate to high	Can protect handling, storage, or sterility performance
Closed-system transfer device	Moderate to high	Device claims may create commercial barriers
Manufacturing process	Moderate	Useful where process improves quality or yield
Ready-to-use presentation	Low to moderate	Differentiation depends on packaging and workflow
Preservative-free multi-dose system	Moderate to high	Requires validated sterile access technology

A commercially meaningful patent strategy would likely focus on a combination of formulation, container, and use claims. Examples include a benzyl alcohol concentration that improves compatibility with a defined class of peptides, a vial system that limits preservative evaporation, or a multi-dose package incorporating a sterile access device.

Broad claims covering "bacteriostatic sodium chloride" alone would face substantial validity and obviousness risks because the product concept is established and commercially familiar.

What is the Orange Book status of Bacteriostatic Sodium Chloride?

The Orange Book is relevant only to the extent that a specific finished product is approved under a drug application and listed with associated patents or exclusivity. A conventional bacteriostatic sodium chloride product does not have new chemical entity exclusivity because sodium chloride and benzyl alcohol are established substances.

For a standard product, the likely exclusivity profile is:

Exclusivity category	Expected position
New chemical entity exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable unless tied to an unrelated specialized indication
Pediatric exclusivity	Product-specific and uncommon
New clinical investigation exclusivity	Possible only with qualifying clinical evidence
Formulation patent exclusivity	Limited and product-specific
Manufacturing patent exclusivity	Possible but difficult to enforce against different processes
Regulatory approval barrier	More significant than composition patents

The decisive issue is the approved application and its labeling, not the chemical identity of sodium chloride. FDA drug listing and application records, DailyMed labeling, and Orange Book entries should be assessed at the specific product level (U.S. Food and Drug Administration, 2024a; U.S. Food and Drug Administration, 2024b).

When does Bacteriostatic Sodium Chloride lose exclusivity?

A conventional product generally has no meaningful patent expiry date that determines market entry. The practical market-entry timeline is governed by regulatory approval, manufacturing readiness, and procurement qualification.

Generic and competitor entry

Competitors may enter through an abbreviated or other applicable FDA pathway if they can demonstrate pharmaceutical equivalence, bioequivalence where required, manufacturing compliance, and appropriate labeling. For a simple injectable solution, manufacturing and quality requirements can be more difficult than the formulation itself.

Key entry requirements include:

• Sterile injectable facility capability
• Validated aseptic processing or terminal sterilization, if appropriate
• Container-closure integrity
• Endotoxin and sterility controls
• Extractables and leachables data
• Preservative-effectiveness data
• Stability data
• Labeling that addresses benzyl alcohol restrictions
• Demonstrated compatibility with the proposed use

Paragraph IV litigation is less likely for a basic bacteriostatic sodium chloride product than for a complex drug. If a sponsor owns a formulation, delivery-system, or container patent, a competitor could challenge that patent through a Paragraph IV certification. The commercial value of such litigation would depend on whether the patent covers a required product characteristic or only an optional presentation.

What patent litigation affects Bacteriostatic Sodium Chloride?

No major patent-litigation pattern is associated with the basic sodium chloride and benzyl alcohol formulation. The principal legal risks are more likely to arise from:

• Trade-secret manufacturing processes
• Device patents covering sterile access systems
• Packaging patents
• Contract manufacturing agreements
• Trademark disputes
• Regulatory exclusivity disputes
• Product-liability claims involving preservative exposure
• Supply and quality disputes

Settlement agreements are unlikely to be central to market access unless a sponsor has created a differentiated device or specialty formulation with enforceable claims. The standard product is closer to a manufacturing and procurement business than a patent-protected branded pharmaceutical.

Which companies are challenging or competing in the market?

Competition is typically based on hospital supply, contract manufacturing, injectable portfolio breadth, and shortage resilience. Relevant participants may include large generic injectable manufacturers, contract development and manufacturing organizations, and hospital-supply companies.

The competitive field can include:

• Pfizer and Hospira-branded injectable operations
• Hikma Pharmaceuticals
• Fresenius Kabi
• Baxter
• Sandoz
• Piramal Pharma Solutions
• Smaller 503B outsourcing facilities for permitted compounding activities
• Regional sterile injectable manufacturers

The relevant commercial distinction is often product availability rather than clinical superiority. Hospitals may qualify multiple suppliers because shortages of basic injectable products can disrupt compounding and drug administration workflows. FDA drug shortage records should be monitored for sodium chloride injection and related diluent presentations (U.S. Food and Drug Administration, 2024c).

What commercial opportunities exist for Bacteriostatic Sodium Chloride?

Hospital and outpatient supply

Hospitals use sodium chloride injection products across pharmacy, anesthesia, infusion, emergency, and procedural settings. A bacteriostatic multi-dose vial can reduce repeated purchases where the labeled use permits multi-dose access.

Commercial advantages include:

• Reliable supply
• Consistent vial dimensions
• Easy pharmacy storage
• Low breakage packaging
• Barcoded inventory management
• Multiple vial sizes
• Competitive contract pricing

Specialty drug reconstitution

The product can be positioned as a diluent for selected injectable therapies, provided compatibility is established. High-value opportunities may exist in:

• Specialty clinics
• Compounding pharmacies
• Hormone and peptide therapies
• Research-use workflows
• Home-injection support
• Veterinary medicine

Marketing must remain within the approved labeling and applicable compounding rules. Compatibility claims should be supported by drug-specific data rather than inferred from sodium chloride concentration alone.

Small-volume formats

A 10 mL or 20 mL vial can serve a different workflow from a 30 mL vial. Smaller volumes reduce waste for low-dose reconstitution, while larger multi-dose vials may improve utilization in high-throughput settings.

Potential portfolio structure:

Presentation	Target customer
10 mL preservative-free vial	Pediatric and sensitive-use settings
20 mL bacteriostatic vial	Outpatient and specialty clinics
30 mL multi-dose vial	General pharmacy and procedural use
50 mL or larger vial	Institutional or repeated-use workflows
Prefilled syringe	Controlled outpatient administration
Closed-system vial	High-containment or workflow-sensitive settings

Private-label and contract manufacturing

Private-label supply is an attractive opportunity because the formulation is standardized and many buyers value dependable access over brand identity. A manufacturer with excess sterile capacity can offer:

• Product development
• Regulatory filing support
• Commercial-scale fill-finish
• Packaging customization
• Stability programs
• Regional distribution
• Dual-source supply agreements

The principal constraints are facility qualification, minimum batch sizes, regulatory ownership, and long-term supply commitments.

How strong is the patent estate for Bacteriostatic Sodium Chloride?

The patent estate is weak for the basic composition and potentially stronger for integrated delivery systems.

Strength assessment

Risk category	Assessment
Basic composition patent risk	Low
Active ingredient patent risk	None in practical terms
Preservative patent risk	Low
Container-closure patent risk	Moderate
Device patent risk	Moderate to high
Manufacturing-process patent risk	Moderate
Regulatory exclusivity risk	Low to moderate
Freedom-to-operate complexity	Low for basic vial; higher for devices

A sponsor should invest in patents only where the formulation or package delivers measurable performance, such as longer in-use stability, lower benzyl alcohol loss, reduced particulate formation, improved drug recovery, or validated multi-dose sterility.

What manufacturing and IP barriers matter most?

The principal barriers are operational.

Manufacturing barriers

Sterile injectable manufacturing requires:

• Qualified cleanrooms
• Validated aseptic processes
• Environmental monitoring
• Sterilizing filtration where applicable
• Media fills
• Validated cleaning and disinfection
• Container-closure integrity testing
• Endotoxin control
• Visual inspection
• Stability programs
• Quality systems consistent with current good manufacturing practice

These requirements create meaningful capital and execution barriers even when patent protection is minimal (U.S. Food and Drug Administration, 2023).

Intellectual-property barriers

The most relevant IP assets may include:

• Vial and stopper combinations
• Closed-system transfer devices
• Low-sorption polymer containers
• Preservative-stabilization methods
• Drug-specific compatibility data
• Automated filling and inspection processes
• Trade secrets related to particulate and endotoxin control

Trade secrets can be commercially important because competitors may reproduce the final composition while lacking the same yield, stability, or defect-rate performance.

How does Bacteriostatic Sodium Chloride compare with sterile water and normal saline?

Product	Preservative	Primary use	Main limitation
Bacteriostatic sodium chloride	Usually benzyl alcohol	Repeated-use diluent	Benzyl alcohol exposure
Preservative-free 0.9% sodium chloride	None	Diluent, flushing, fluid replacement	Usually single-dose or limited reuse
Bacteriostatic water for injection	Usually benzyl alcohol	Reconstitution vehicle	No sodium chloride tonicity
Sterile water for injection	None	Reconstitution	Hypotonic if administered without solute
Lactated Ringer's	None	Fluid replacement	Greater drug incompatibility potential

Bacteriostatic sodium chloride is most attractive when both tonicity and multi-dose preservation are useful. Preservative-free normal saline has a broader safety profile but may generate more waste and require single-dose handling.

Key Takeaways

• Bacteriostatic Sodium Chloride Injection is usually a 0.9% sodium chloride solution preserved with approximately 0.9% benzyl alcohol.
• The basic formulation has little practical composition-patent value.
• Commercial protection depends on sterile manufacturing, supply reliability, container design, labeling, and customer qualification.
• Preservative-free and low-volume presentations offer the clearest product-line expansion opportunities.
• Benzyl alcohol exposure is the central safety and labeling issue.
• Container-closure systems and closed-system transfer devices offer stronger IP opportunities than the solution itself.
• Paragraph IV litigation is unlikely to be important for the basic product but could arise around differentiated packaging or delivery systems.
• Contract manufacturing and private-label supply can produce better returns than a heavily branded standard product.
• Drug-specific compatibility data can create a defensible commercial position without relying on broad formulation patents.
• Manufacturing execution and regulatory compliance are the primary barriers to entry.

FAQs

Is bacteriostatic sodium chloride an excipient or a finished drug product?

It is generally a finished injectable drug product used as a diluent or vehicle. Sodium chloride and benzyl alcohol are its principal formulation ingredients.

Can benzyl alcohol be replaced with another preservative?

Yes, in principle, but the replacement would require new antimicrobial-effectiveness, stability, compatibility, toxicology, packaging, and regulatory support. For a basic product, replacement may not provide sufficient commercial value unless it targets a defined patient population.

Is bacteriostatic sodium chloride suitable for neonatal use?

Products containing benzyl alcohol are generally unsuitable for neonates because of benzyl alcohol toxicity concerns. A preservative-free presentation is the more appropriate development strategy for neonatal applications.

Can a company patent a bacteriostatic sodium chloride vial?

A broad patent on the basic sodium chloride and benzyl alcohol solution would likely be weak. Stronger claims may be available for a novel container, sterile access system, preservative-stabilization method, or validated drug-specific compatibility formulation.

What is the highest-value commercial differentiation?

The strongest opportunities are preservative-free specialty presentations, closed-system multi-dose packaging, dependable supply, low-volume formats, and compatibility data for high-value injectable therapies.

References

1. Pfizer Inc. (2023). Bacteriostatic sodium chloride injection, USP 0.9%: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. United States Food and Drug Administration. (2023). Current good manufacturing practice requirements for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. https://www.ecfr.gov/

3. United States Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. United States Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. United States Food and Drug Administration. (2024c). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages

6. United States Pharmacopeia. (2023). General chapter <51>: Antimicrobial effectiveness testing. In United States Pharmacopeia and National Formulary.

7. United States Pharmacopeia. (2023). General chapters <71> and <1207>: Sterility tests and package integrity evaluation. In United States Pharmacopeia and National Formulary.